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Assessment of brain reference 
genes for RT-qPCR studies in 
neurodegenerative diseases
Rasmus Rydbirk1, Jonas Folke1, Kristian Winge2,3,4, Susana Aznar1, Bente Pakkenberg1,4 & 
Tomasz Brudek1
Evaluation of gene expression levels by reverse transcription quantitative real-time PCR (RT-qPCR) 
has for many years been the favourite approach for discovering disease-associated alterations. 
Normalization of results to stably expressed reference genes (RGs) is pivotal to obtain reliable results. 
This is especially important in relation to neurodegenerative diseases where disease-related structural 
changes may affect the most commonly used RGs. We analysed 15 candidate RGs in 98 brain samples 
from two brain regions from Alzheimer’s disease (AD), Parkinson’s disease (PD), Multiple System 
Atrophy, and Progressive Supranuclear Palsy patients. Using RefFinder, a web-based tool for evaluating 
RG stability, we identified the most stable RGs to be UBE2D2, CYC1, and RPL13 which we recommend 
for future RT-qPCR studies on human brain tissue from these patients. None of the investigated genes 
were affected by experimental variables such as RIN, PMI, or age. Findings were further validated by 
expression analyses of a target gene GSK3B, known to be affected by AD and PD. We obtained high 
variations in GSK3B levels when contrasting the results using different sets of common RG underlining 
the importance of a priori validation of RGs for RT-qPCR studies.
Reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) is one of the most widely used 
methods for analysis of gene expression levels due to its methodological accessibility and high sensitivity. Studies 
on neurodegenerative diseases are no exceptions, and RT-qPCR have helped to identify gene expression changes 
and thereby disease-associated genes in several disorders, e.g. Alzheimer’s disease (AD)1–4, and Parkinson’s dis-
ease (PD)5–7. Identification of small, dynamic changes in gene expression is important for understanding of the 
mechanisms underlying neurodegenerative events. An essential step in the development of RT-qPCR assays is 
identification of appropriate reference genes (RGs) to be used as endogenous controls in data normalization. 
Housekeeping genes (HKGs) are often the most obvious choice as constitutive RGs since HKGs are important for 
basal cellular functions and should therefore exhibit stable levels under normal and pathophysiological condi-
tions. However, it has been shown that expression levels of many HKGs can also be affected by disease-mediated 
pathological changes in, e.g., cell homeostasis and metabolism8,9. Thus, the selection of stable RGs is critical in 
order to avoid methodological errors. For many years, glyceraldehyde 3-phospate dehydrogenase (GAPDH) and 
beta(β )-actin (ACTB) have been the primary choices as RGs. Though, in the last decade a vast number of studies 
have documented that these genes should be used with caution since they may display variable expression levels 
across various cell types and disease states10–14.
Descriptive statistics is the most straightforward way for comparing RG expression stability. Even though 
widely applied, this approach has its pitfalls due to its simplicity. There are several more advanced methods avail-
able that address the problem of RG transcription stability taking into account multiple parameters. The four 
most common are the Δ Ct-method15 and the three algorithms Genorm16, BestKeeper17, and NormFinder18 
(reviewed elsewhere19). RefFinder, a free online software platform for identification of stable RGs, derives a 
comprehensive ranking based on the geometric mean of the scores from Genorm, BestKeeper, NormFinder, 
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and the Δ Ct-method in order to extract the best RGs based on the different mathematical approaches20. Although 
these methods differ in their mathematical design, studies have shown only small variations in the outcomes for 
Genorm, NormFinder, and BestKeeper, and also between the stand-alone applications for Genorm, NormFinder, 
and BestKeeper, and RefFinder, making these methods comparable21,22.
The overall aim for this study was to evaluate putative RGs for use in gene expression studies on the human 
brains in diverse, but pathologically related neurodegenerative diseases. Here, we report on 15 candidate RGs 
that potentially can be used for normalization of gene expression data in brain samples from patients diagnosed 
with AD, PD, Multiple System Atrophy (MSA), or Progressive Supranuclear Palsy (PSP) compared with normal, 
non-neurological affected controls (NCs). We selected RG candidates based on their extensive use in RT-qPCR 
studies from the literature as well as their presence in ready to use commercial kits for RG selection. Several of 
the RG candidates have previously been investigated under different conditions10,12,23–26, and a few have been 
tested in AD and/or PD11,27,28. MSA and PSP are atypical parkinsonian disorders and have a clinical manifestation 
highly similar to PD29. To our knowledge, no study on RG selection has been performed on MSA or PSP thus 
far. Hence, assessment of stable RGs for comparative studies on PD, MSA, and PSP is highly relevant in order to 
strengthen the reliability of the experimental outcome. Furthermore, although PSP is clinically comparable to 
PD, the pathological events in PSP are similar to AD30. We investigated two disease-affected brain regions, the 
medial frontal gyrus of the prefrontal cortex (PFC), and the cerebellum (CB), in order to define the most stable 
set of RGs for comparative gene expression studies in PD, MSA, PSP, and AD brains. The following genes were 
investigated (Table 1): GAPDH, ACTB, ribosomal protein large 13 (RPL13), hypoxanhine phosphoribosyl trans-
ferase (HPRT1), cytrochrome C1 (CYC1), topoisomerase 1 (TOP1), eukaryotic translation initiation factor 4A2 
(EIF4A2), β -2-microglobulin (B2M), pumilio-homolog 1 (PUM1), TATA-box binding protein (TBP), ubiquitin C 
(UBC), cyclophilin A (PPIA), succinate dehydrogenase complex subunit A (SDHA), ATP synthase H+ transport-
ing mitochondrial F1 complex beta polypeptide (ATP5B), and ubiquitin-conjugating enzyme E2D2 (UBE2D2). 
Further, glycogen synthase kinase 3β (GSK3B) was included as a Gene of Interest (GOI) to validate the impact of 
the RG selection on normalization of gene expression data.
Results
RT-qPCR primer amplification efficiencies. Primer efficiencies were calculated for each candidate RG 
and ranged between 90.4% and 107.6% using a minimum of four points on the standard curve with R2-values 
ranging from 0.992 to 1.000 (Table 1). Each reaction ended with a melting curve analysis between 55 and 95 °C 
for PCR product evaluation (Fig. S1). If melting curve analysis identified presence of primer dimers, an additional 
acquisition step was added in each PCR cycle (Table 1) since primer dimers do not generate signal in fluorescence 
captured over 76 °C. Due to low expression levels in both brain regions (cycle threshold (Ct)mean > 35) and since it 
Gene 
symbol Accession no. Primer sequence (5′-3′) Bp E (%) R2 Ta Taq
ATP5B NM_001686 Sense:Anti-sense:
TCACCCAGGCTGGTTCAGA
AGTGGCCAGGGTAGGCTGAT 80 106.3 0.996 60
B2M NM_004048 Sense:Anti-sense:
ACTGAATTCACCCCCACTGA
CCTCCATGATGCTGCTTACA 114 102.7 0.997 56
PPIA NM_021130 Sense:Anti-sense:
TCCTGGCATCTTGTCCATG
CCATCCAACCACTCAGTCTTG 90 101.5 1.000 58
CYC1 NM_001916 Sense:Anti-sense:
AGCCTACAAGAAAGTTTGCCTAT
TCTTCTTCCGGTAGTGGATCTTGGC 126 104.3 1.000 58 80
EIF4A2 NM_001967 Sense:Anti-sense:
AATTCCGGTCAGGGTCAAGTC
GCCACACCTTTCCTCCCAAA 166 102.0 0.994 56
GADPH NM_002046 Sense:Anti-sense:
CGCTCTCTGCTCCTCCTGTT
CCATGGTGTCTGAGCGATGT 81 101.5 0.999 60
PUM1 NM_014676 Sense:Anti-sense:
AGTGGGGGACTAGGCGTTAG
GTTTTCATCACTGTCTGCATCC 111 97.8 0.997 58
RPL13 NM_000977 Sense:Anti-sense:
CCTGGAGGAGAAGAGGAAAGAGA
TTGAGGACCTCTGTGTATTTGTCAA 126 90.4 0.998 56
TBP NM_003194 Sense:Anti-sense:
GCCCGAAACGCCGAATATAA
AATCAGTGCCGTGGTTCGTG 81 100.2 1.000 58
TOP1 NM_003286 Sense:Anti-sense:
GGCGAGTGAATCTAAGGATAATGAA
TGGATATCTTAAAGGGTACAGCGAA 97 99.5 0.992 56
UBC NM_021009 Sense:Anti-sense:
CACTTGGTCCTGCGCTTGA
TTATTGGGAATGCAACAACTTTAT 104 101.3 0.993 56
UBE2D2 NM_003339 Sense:Anti-sense:
TGCCTGAGATTGCTCGGATCT
TCGCATACTTCTGAGTCCATTCC 81 107.6 0.999 58
ACTB NM_001101 Sense:Anti-sense:
TGACATTAAGGAGAAGCTGTGCTAC
ACTTCATGATGGAGTTGAAGGTAGT 224 104.0 0.990 60 82
GSK3B NM_002093 Sense:Anti-sense:
ACAACAGTGGTGGCAACTCC
TTCTTGATGGCGACCAGTTCT 146 93.0 0.989 60
Table 1.  Overview of genes and corresponding primer pairs for reverse transcriptase quantitative real-
time PCR. R2 and the primer efficiency, E, was calculated using at least four points on the standard curve.  
Bp: length of the amplicon in base pair; Ta: Annealing temperature [°C]; Taq: Acquisition temperature [°C].
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was not possible to obtain good efficiency for HPRT1 and SDHA, the genes were not included in the subsequent 
stability measurements.
Descriptive statistics of candidate RGs. Almost all candidate RGs showed significantly aberrant expres-
sion levels between the disease groups in both brain regions with the exception of RPL13, EIF4A2, B2M, and UBC 
in the PFC which showed no significant differences between groups (Fig. 1). Ct-values for the 13 included candi-
date RGs in the PFC and CB for all five groups ranged between 19.9 and 38.7 (Fig. 1, Table 2). The standard devi-
ations (SDs) ranged between 0.66 and 3.09 (Table 2). In the PFC, EIF4A2 had the lowest expression levels (mean 
Ct (Ctmean) = 32.6) followed by TBP (Ctmean = 31.5), and B2M (Ctmean = 30.3). In the CB PUM1 (Ctmean = 32.8), 
TOP1 (Ctmean = 31.0), and TBP (Ctmean = 30.9) exhibited the lowest expression levels. The genes with the highest 
expression levels were in both brain regions RPL13 (Ctmean, PFC = 25.0 and Ctmean, CB = 23.5), and PPIA (Ctmean, PFC 
= 25.7 and Ctmean, CB = 27.1). In all groups, EIF4A2 showed the most variable expression levels in both regions 
reflected by the mean SD (SDmean, PFC = 2.18 and SDmean, CB = 1.80). In both brain regions, the RG candidates that 
exhibited the lowest variability in expression levels were TBP (SDmean, PFC = 1.21 and SDmean, CB = 1.09), PUM1 
(SDmean, PFC = 1.24 and SDmean, CB = 1.05), and RPL13 (SDmean, PFC = 1.33 and SDmean, CB = 1.24).
Summarized comprehensive ranking. Based on the outcome from the RefFinder software (for all results, 
see Excel S1), candidate RGs were assigned a rank from 1 to 13 (1 being the most stable RG in the given combina-
tion of disease groups and 13 being the least stable; Excel S1). When integrating all different combinations for all 
disease groups included in the study, we found that in both brain regions CYC1 and UBE2D2 were the most stable 
RGs (Fig. 2). The least stable RG candidates in the PFC were GAPDH and EIF4A2, while EIF4A2 and TOP1 were 
ranked the least stable in the CB. Further, the summarized, comprehensive rankings for both brain regions and all 
individuals were considered collectively. CYC1, UBE2D2, and RPL13 were ranked among the top six most stable 
RGs as illustrated in Fig. 3A. Of the seven most unstable RGs, EIF4A2, B2M, UBC, and ACTB were identified in 
both the PFC and CB (Fig. 3B). The overall three most stable RGs identified in this study are CYC1, UBE2D2, and 
RPL13 (Fig. 3).
Reference gene validation. In order to demonstrate the impact of the RG choice on RT-qPCR data nor-
malization, target gene GSK3B expression levels were analysed in both the PFC and the CB, between NCs and AD 
Figure 1. Thirteen candidate reference gene Ct-value distributions in both brain areas. Box and whisker 
plots showing RT-qPCR mRNA expression levels depicted as raw Ct-values in the prefrontal cortex (A) and 
the cerebellum (B) for all Alzheimer’s disease (AD), Parkinson’s disease (PD), Multiple System Atrophy (MSA), 
Progressive Supranuclear Palsy (PSP), and normal, non-demented controls (NCs). Boxes depict the 25th, 50th 
and 75th percentiles; whiskers show the minimum and maximum values for each RG. p-values indicate the 
ANOVA significance levels.
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(Fig. 4A,B), NCs and PD (Fig. 4C,D), as well as between all groups (Fig. 4E–J). For each combination of disease 
groups, data were normalized to three distinct sets of RGs: 1) GAPDH and ACTB, the two most commonly used 
RGs; 2) the two RG candidates that in our analyses displayed the lowest stability for the given combination of 
disease groups; and 3) the three most stable RG candidates that in our analysis displayed the highest stability 
for the given combination of disease groups. The gene expression levels measured for GSK3B were significantly 
influenced by the choice of RGs used for normalization (Fig. 4, summarized in Table 3).
The greatest effect on the results is seen for the analysis of data from NCs vs AD. The expression of GSK3B is 
significantly upregulated in AD when normalized to the most common RGs and the least stable RGs in the PFC 
(Fig. 4A), and to the most common RGs in the CB (Fig. 4B). However, when we normalized the GSK3B expres-
sion levels to the most stable RGs obtained by our analyses, the relative significance between the groups disap-
peared in PFC (Fig. 4A) or is swapped in CB (Fig. 4B). For NCs vs PD normalization to the most common, and 
the most stable RGs resulted in similar outcomes, however, SDs when using the most stable RGs were decreased 
(Fig. 4C,D). When all groups were analysed together and GSK3B levels were normalized to the most stable RGs 
we observed the most equal, least diverging results between groups (Fig. 4I,J). A high increase of GSK3B levels in 
the AD group vs. other groups was observed in the PFC for data normalized to both the least stable RGs (Fig. 4G) 
and the most common RGs (Fig. 4E). Conversely, decreased levels of GSK3B were observed in the AD patients 
compared to NCs when the least stable RGs were used for data normalization in the CB (Fig. 4H), whereas no 
differences were identified in the CB for the most stable RGs (Fig. 4J).
Correlation analyses. Significant differences in RNA integrity number (RIN) values, age, and post-mortem 
intervals (PMIs) were observed between groups (Table 4). To evaluate the impact of these factors on expression of 
GSK3B, raw Ct-values, and Ct-values normalized to the most stable RGs were correlated to RIN-values, age, and 
PMIs (Table S3). None of the viable factors showed significant correlation to the expression of GSK3B.
Discussion
Our study is the first to provide a comprehensive evaluation of commonly used RGs for RT-qPCR for compar-
ative studies of four neurodegenerative diseases: Two highly investigated diseases, AD and PD, along with two 
rare diseases, MSA and PSP. There is a general consensus on the use of HKGs as RGs, however, it has become 
more evident that the assumption of RG stability is not consistent when experimental conditions are altered. 
Gene Region
NC
SD
AD
SD
PD
SD
MSA
SD
PSP
SD
Average
Mean Mean Mean Mean Mean Ct SD
ACTB PFC 26.9 2.67 26.7 1.46 28.9 2.22 29.4 1.47 29.6 1.68 28.3 1.90
CB 29.8 1.42 29.1 1.26 29.9 0.68 30.3 1.21 32.4 2.31 30.3 1.38
ATP5B PFC 27.6 2.68 26.9 0.89 29.9 1.46 30.5 1.25 30.0 1.75 29.0 1.61
CB 29.9 1.27 28.0 1.34 29.7 1.07 29.3 1.57 31.0 2.03 29.6 1.46
B2M PFC 30.9 3.09 29.9 1.30 29.3 1.35 30.8 1.77 30.7 0.96 30.3 1.69
CB 30.5 1.32 28.0 1.61 29.9 1.11 28.9 1.26 31.0 1.98 29.6 1.46
PPIA PFC 24.7 2.40 23.9 1.15 26.3 1.07 27.0 1.09 26.3 1.26 25.7 1.39
CB 27.5 0.79 24.7 1.26 27.0 0.96 26.8 1.37 29.5 2.50 27.1 1.38
CYC1 PFC 26.8 2.25 26.3 1.35 27.9 1.02 28.6 1.05 28.1 1.20 27.6 1.37
CB 27.8 1.11 24.9 1.11 27.4 1.05 27.3 1.44 29.3 2.34 27.3 1.41
EIF4A2 PFC 33.6 3.09 32.5 2.31 31.7 1.64 32.8 1.99 32.5 1.85 32.6 2.18
CB 31.1 1.49 28.5 1.88 30.5 1.18 30.3 1.92 31.4 2.51 30.4 1.80
GADPH PFC 26.2 2.45 31.9 3.07 28.1 1.49 28.8 1.28 28.4 1.77 28.7 2.01
CB 27.1 1.32 26.1 1.21 26.7 1.03 26.7 1.33 28.9 1.94 27.1 1.37
PUM1 PFC 29.3 1.97 28.4 1.25 30.9 1.01 31.5 0.90 31.3 1.07 30.3 1.24
CB 33.5 1.09 31.5 0.66 32.7 0.95 32.4 1.10 34.1 1.47 32.8 1.05
RPL13 PFC 24.8 1.95 24.3 1.80 24.7 0.91 25.4 0.89 25.4 1.12 25.0 1.33
CB 24.1 1.20 21.3 0.96 23.4 0.90 23.7 1.33 24.9 1.79 23.5 1.24
TBP PFC 29.9 1.84 29.2 1.32 32.6 0.97 33.3 0.81 32.7 1.09 31.5 1.21
CB 31.5 1.03 29.0 1.13 31.2 1.21 30.7 1.07 32.0 1.03 30.9 1.09
TOP1 PFC 29.8 2.55 28.7 1.73 30.1 1.13 31.3 1.28 30.6 1.47 30.1 1.63
CB 32.4 1.04 28.0 0.68 31.4 0.87 31.4 1.65 32.0 2.14 31.0 1.28
UBC PFC 29.3 2.55 28.1 2.88 28.1 1.06 28.9 0.93 28.3 1.14 28.5 1.71
CB 28.0 1.02 24.7 1.09 27.7 1.28 28.0 1.17 29.9 1.96 27.7 1.30
UBE2D2 PFC 29.5 2.31 28.8 1.54 30.1 0.98 31.0 0.99 30.2 1.30 29.9 1.42
CB 30.4 0.99 27.5 1.16 29.9 0.76 29.7 1.52 31.5 1.81 29.8 1.25
Table 2.  Mean raw Ct-values and standard deviations (SDs) for each disease group and controls in both the 
prefrontal cortex, and the cerebellum. NC: Normal controls; AD: Alzheimer’s disease; PD: Parkinson’s disease; 
MSA: Multiple System Atrophy; PSP: Progressive Supranuclear Palsy; PFC: Prefrontal cortex; CB: Cerebellum. 
Means are geometric.
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Therefore, we agree with others that, optimally, selection of the most valid RGs should be performed individually 
for each experimental setup31 as well as the investigated tissue, organ and region, disease, species and so forth11. 
Additional factors such as primer efficiencies, primer sequences, cDNA synthesis protocols, and basic experimen-
tal differences could also influence the outcome in RG stability, and therefore should also be considered. Several 
other factors have also been shown to influence the output of mRNA studies including degree of degradation32,33, 
PMIs34, and subject age35. As suggested by the minimum information for publication of quantitative real-time 
experiments (MIQE) guidelines36 RNA fragmentation should be obtained for every mRNA sample used for 
RT-qPCR. One way to obtain this is by determining the RIN-values37. It is important to obtain RIN-values as 
high as possible, as done in this study, with a threshold of 3.95 recommended for human post-mortem studies38. 
However, short amplicons (below 250 base pairs) are less dependent on RIN-values33. Further, some of the prob-
lems associated with low RIN-values can be circumvented using internal RGs for data normalization together 
Figure 2. Summarized gene stability ranking for all individuals in the prefrontal cortex (A) and the cerebellum 
(B). Summarized rankings from RefFinder. Lower ranking indicates higher stability.
Figure 3. Ven diagram showing the overlap of the six most stable (A) and seven least stable (B) reference 
genes in both the prefrontal cortex (light gray) and the cerebellum (dark gray). The ven diagram is based on the 
summarized comprehensive rankings from RefFinder.
www.nature.com/scientificreports/
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Figure 4. Expression levels of GSK3B normalized to different reference genes (RGs). GSK3B expression 
levels were analyzed using the common RG choices (GAPDH and ACTB) in combination, using the two 
lowest ranked genes in combination, and using the three best ranked genes in combination. (A) and B) shows 
comparison of RG choice for normal, non-demented controls (NCs) and Alzheimer’s disease (AD) patients, 
(C) and (D) for NCs and Parkinson’s disease (PD) patients, (E–H) for all groups. (A,C,E,G) and (I) show 
comparisons for the prefrontal cortex, and (B,D,F,H) and (J) for the cerebellum. All data are presented as the 
relative expression levels normalized to the most stable RGs calculated for each combination of disease groups 
in the respective areas, and data are shown in relation to expression levels in NCs. MSA: Multiple System 
Atrophy patients; PSP: Progressive Supranuclear Palsy patients. Data are presented as mean ± SEM. *p < 0.05, 
**p < 0.01, ***p < 0.001.
www.nature.com/scientificreports/
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with expressing result values relative to an internal standard (the Δ Δ Ct method39) with correction for PCR 
efficiency32. RIN-values have been shown to correlate negatively with PMIs34, however, we did not identify an 
influence of either PMIs or age on RIN-values (Fig. S2). We further corroborated that the raw or normalized 
Ct-values for GSK3B expression levels did not correlate with any of those factors in both brain regions. Thus, 
we can conclude that by applying the recommendations from the MIQE guidelines, and by implementing the 
precautions in the experimental design as described here, we were able to perform relative quantification of gene 
expression levels with a minimum risk of false interpretation of the results.
As mentioned above, PMIs varied significantly between groups. The samples used in this study originated 
from three different brain banks placed in Denmark, the Netherlands, and the USA. The variations in PMIs are 
primarily due to differences in national legislations regarding PMIs after which the extraction of human brains is 
allowed, and this is therefore difficult to circumvent. Since our findings did not show any significant correlations 
between PMI and RIN, age, raw Ct-values, or normalized Ct-values, this study moreover supports that inclusion 
of human brain samples from different sources is feasible even in the case of large differences in PMIs.
We applied the RefFinder software in this study for data analysis. The software combines four of the most com-
monly used algorithms for determination of the stability of gene expression (Genorm, NormFinder, BestKeeper 
and the Δ Ct-method), but RefFinder does not share all of the features that are included in the stand-alone appli-
cations. E.g., the capability of Genorm to define the optimal number of RGs using a predetermined cut-off value 
that determines how much adding another RG to the analyses affects the grouped stability of the best ranked 
RGs16. However, as already stated elsewhere16,40, using a minimum of three RGs should be appropriate, and we 
therefore do not consider the absence of this feature in RefFinder to be of relevance for our analysis. RefFinder 
does not take primer efficiencies into account, a feature included in the Genorm, NormFinder and BestKeeper 
stand-alone applications. In order to correct for this, we manually adjusted the raw Ct-values for efficiencies 
before analysis. This has previously proved to make results obtained with the RefFinder software comparable to 
those obtained with the stand-alone applications22. Similar and comparable evaluations are obtained from the 
Groups
Most common RGs Least stable RGs Most stable RGs
% of NC p-value1 % of NC p-value1 % of NC p-value1
PFC
 NC vs AD¤ 2015.9 0.009 1150.9 0.009 107.2 0.741
 NC vs AD¤ 105.3 0.839 8.2 <0.001 64.9 0.022
 All groups+ — 0.004 NC&MSA > PD* 0.001 — 0.015
CB
 NC vs AD¤ 208.6 0.012 25.3 <0.001 57.6 0.010
 NC vs AD¤ 93.5 0.660 57.5 0.023 81.7 0.245
 All groups+ — 0.080 NC > AD* 0.043 — 0.383
Table 3.  Results from GSK3B expression comparison. GSK3B: Glycogen synthase kinase-3beta; RG: 
Reference gene; NC: Normal control; AD: Alzheimer’s disease; PD: Parkinson’s disease; MSA: Multiple System 
Atrophy. 1p-values for the t-test or the ANOVA test are listed. Data were analyzed using: ¤Welch’s t-test or 
Student’s t-test; +Welch’s weighted ANOVA followed by Games-Howell post-hoc test (*p < 0.05).
Region
Patient 
group Origin N
Braak 
stage Sex
Age 
[years] PMI [hours] RIN
PFC NC NBB 10 1.3 ± 0.5 4M/6F 81.0 ± 9.5 9.2 ± 5.8 5.1 ± 0.6
AD NBB 10 4.7 ± 0.7 4M/6F 81.9 ± 8.5 4.7 ± 1.1 5.0 ± 0.6
MSA BBH 10 — 4M/6F 64.4 ± 6.8 41.6 ± 24.1 5.1 ± 0.7
PD HV 10 — 7M/3F 79.5 ± 6.0 18.3 ± 6.9 5.8 ± 0.9
PSP 7BBH/3HV 10 — 8M/2F 72.4 ± 8.7 30.1 ± 15.1 5.8 ± 1.0
p-value 0.0001 0.190*  < 0.001  < 0.001 0.055
CB NC BBH 10 — 4M/6F 72.1 ± 7.8 36.3 ± 18.0 6.7 ± 0.5
AD NBB 10 4.7 ± 0.7 5M/5F 78,6 ± 7.6 5.1 ± 2.5 6.1 ± 1.1
MSA BBH 8 — 2 M/6 F 63.9 ± 7.7 43.8 ± 16.9 5.4 ± 0.8
PD HV 10 — 8 M/2 F 78.1 ± 7.2 17.8 ± 5.5 6.1 ± 0.5
PSP 7BBH/3HV 10 — 8 M/2 F 74.9 ± 8.1 33.0 ± 17.0 6.0 ± 1.1
p-value — 0.061* 0.002  < 0.001 0.036
Table 4.  Main clinical and neuropathological data for patient groups in the prefrontal cortex, and the 
cerebellum. NC: Normal control; AD: Alzheimer’s disease; PD: Parkinson’s disease; MSA: Multiple System 
Atrophy; PSP: Progressive Supranuclear Palsy; PFC: Prefrontal cortex; CB: Cerebellum; NBB: Netherlands Brain 
Bank; BBH: Bispebjerg-Frederiksberg University Hospital Brain Bank; HV: Harvard Brain Tissue Resource 
Center; M: male; F: female; RIN: RNA integrity number. p-values: One-Way ANOVA followed by Tukey’s post-
hoc test. *Chi-Squared test of independence.
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Genorm, NormFinder, and the Δ Ct-methods, with deviations for some genes obtained from BestKeeper. This 
is surprising as earlier findings showed equal stability rankings for Genorm, NormFinder, and BestKeeper21,22. 
An explanation could be the so-called BestKeeper index, a tool that only BestKeeper applies. This index is the 
geometric mean of the Ct-values of all candidate RGs grouped together. Thus, the gene with the highest coefficient 
of correlation with the index indicates the highest stability. Despite of these small discrepancies, results regarding 
the best RG candidates were consistent between the different applied methods.
In this study we have used different approaches to assess RG candidate stabilities. Had we only used descrip-
tive statistics with the only criteria applied being minimal variation in the expression levels in each group fol-
lowed by low differences between disease groups, TBP, PUM1, and RPL13 would be the preferable choices in both 
the PFC and CB in this study. Although RPL13 ranks among the four most stable RGs according to the summa-
rized rankings, TBP ranks among the three least stable RGs and it would therefore be inadvisable to use, whereas 
PUM1 seems to be an intermediate RG. Thus, in order to evaluate candidate RGs based on a wide range of equally 
important parameters more advanced methodical and statistical approaches are needed.
According to our analyses using RefFinder, CYC1, UBE2D2, and RPL13 were ranked among the top six most 
stable RGs, while EIF4A2, B2M, UBC, and ACTB were among the most unstable RGs. CYC1 and UBE2D2 pro-
teins are affected in at least AD and/or PD41–43, but this is apparently irrelevant to the gene expression stability. The 
CYC1 protein is part of the mitochondrial electron transport chain and is thus crucial for cellular respiration44. 
UBE2D2 protein is a ubiquitin-conjugating enzyme that has been proposed as a general HKG along with proteins 
with similar functions45. Our results for UBE2D2 find support elsewhere27. To our knowledge, neither gene tran-
scription nor protein levels of the ribosomal 60S-subunit RPL13 have been reported to be affected in any of the 
diseases included in this study.
As suspected, GAPDH and ACTB did not show up as stable RGs in our analyses. GAPDH protein is a cata-
lytic enzyme involved in glycolysis and is therefore important for cell metabolism46. Most likely due to this vital 
function, GAPDH has been one of the primary choices as RG in RT-qPCR studies for more than two decades. 
However, GAPDH protein and its activity has been shown to be affected in AD8 and PD9, and general GAPDH 
transcription levels have been shown to vary highly between different tissue compartments47. Our data indicate 
that GAPDH is not a stable RG in neither the PFC (ranked 12th) nor the CB (ranked 6th). ACTB protein is one of 
six different human actin isoforms and is one of the two non-muscle cytoskeletal actins48. ACTB has also been 
used extensively as an RG for several years. In our studies ACTB is ranked 7th and 9th in the PFC and CB, respec-
tively, and it is therefore not recommended for use as a RG in similar experimental setups.
Finally, in order to validate how the choice of RGs influences RT-qPCR results, we compared GSK3B mRNA 
levels between different combinations of disease groups. GSK3B is regulating several different cellular processes, 
and GSK3B dysregulation have been implicated in the pathogenesis of both AD and PD49. Substantial divergences 
occurred in the relative transcript abundance of GSK3B when normalized to different sets of reference genes. 
Generally, large variations in the relative expression of GSK3B are seen when the most common, GAPDH and 
ACTB, or the least stable RGs are used for normalization. Conversely, when the most stable RGs are used, relative 
differences in mRNA levels between the groups become minimized. Bearing in mind that GAPDH and ACTB 
proved to be unstable RGs, the spread between these observations confirm the importance of using the adequate 
RGs in order to avoid false results.
In summary, the expression profiles and stability of 13 commonly used RGs in brain samples from four dif-
ferent neurodegenerative disorders (AD, PD, MSA and PSP) and NCs in two distinct brain regions (PFC and 
CB) were investigated using six different statistical approaches (descriptive statistics, Genorm, NormFinder, 
BestKeeper, Δ Ct-method, and RefFinder). Furthermore, the relative expression of the disease associated gene 
GSK3B was assessed using different sets of RGs. This approach validated the impact that the choice of RGs has 
on the study outcome and underlined the importance of selecting the most stable RGs to correctly quantify gene 
expression levels. We suggest performing thorough analyses on RG selection for each tissue, disease, and experi-
mental setup prior to the main experiment. Based on the results from this study we recommend using UBE2D2, 
CYC1, and RPL13 in combination for studies related to brain tissue and to the diseases included here. Further, 
we have provided several important considerations regarding the choice and the assessment of RGs in RT-qPCR 
studies. This report should therefore be regarded as a guideline on how to perform RG validation in order to 
reinforce the reliability of RT-qPCR results.
Methods
Source of human brain tissue. Post-mortem brain samples from the medial frontal gyrus of the PFC 
and the CB (Tables S1 and S2) were generously donated by the Brain Bank at Bispebjerg-Frederiksberg Hospital 
(University of Copenhagen; approved by the Danish Data Protection Agency, j.no. BBH-2010-06, I-suite 00971), 
the Netherlands Brain Bank (Netherlands Institute for Neuroscience), and the Harvard Brain Tissue Resource 
Center (Harvard Medical School Teaching Hospital) (Table S1). All samples were histologically investigated to 
confirm pathology and diagnosis. A significant difference in age in the MSA group is observed due to their earlier 
disease onset and death (Table 4). All brain samples were collected, and handled in accordance with Danish ethi-
cal standards, and the Danish Health and Medicine Authorities. This project was approved by the Regional ethical 
committee of Region Hovedstaden, journal no. H-16025196. Informed consent was obtained from all donors. 
Samples were stored at − 80 °C prior to total RNA extraction.
RNA isolation and cDNA synthesis. The RNA isolation and the subsequent RT-qPCR reactions were 
performed according to the MIQE guidelines36. Total RNA extraction was performed using either Qiagen RNeasy 
Lipid Tissue Mini Kit or Qiagen AllPrep DNA/RNA/miRNA Universal Kit according to manufacturer’s instruc-
tions. Prior to RNA extraction, brain samples were homogenized using a MagNA Lyser instrument (Roche 
Diagnostics) and the related MagNA Lyser green beads (Roche) at 2 × 6.5 k rpm for 25 seconds in 1 ml pre-cooled 
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Qiazol reagent supplied with the extraction kit. RNA quality and concentrations were assessed using the 2100 
Agilent Bioanalyzer (Agilent Technologies) using RNA 6000 Nano kits (Agilent Technologies) following the man-
ufacturer’s instructions. RNA purity was assessed using a NanoDrop 2100 (Thermo Scientific). RNA concentra-
tions ranged from 0.04–1.10 μ g/μ l and RIN-values from 4.0–7.8. A cut-off threshold of RIN = 3.95 based on34,38, 
and an optical density at wavelength 260/280 nm range of 1.8–2.2 were chosen for this study36. All RNA samples 
were subjected to DNase digestion using the Turbo DNA-freeTM Kit (Ambion) and subsequently tested for DNA 
contamination in RT-qPCR using the GAPDH primer set (Table 1). Single-stranded cDNA was synthesized from 
100 ng of total RNA using qScript cDNA SuperMix kit (Quanta) following the manufacturer’s instructions. cDNA 
concentrations were measured on a NanoDrop 2000 and diluted to 100 ng/μ l in RNase-free H2O.
Selection of candidate reference genes and PCR primer design. 15 putative RGs were selected for 
evaluation of their stability in each patient group and in comparisons of patient groups. The RGs were selected 
based on their vast usage in the literature and in commercial gene array kits. Six primer pairs were adapted 
from the literature: ATP5B50, TOP151, PPIA52, PUM153, TBP and UBE2D254. For all other genes primer pairs 
were designed de novo using Primer-BLAST (NCBI) and Oligo 7 (Molecular Biology Insight, Inc.). Primers 
were synthesized by TAG Copenhagen A/S. For each primer pair (Table 1), the optimal annealing temperature, 
the amplification efficiency, and R2 were determined and calculated using the MxPro software package (Agilent 
Technologies).
Reverse Transcriptase Semi-Quantitative Real-time PCR (RT-qPCR). All samples were run in 
duplicates. Briefly, RT-qPCR reactions were carried out using Fast SYBR Green Master Mix (Applied Biosystems) 
on a Stratagene Mx3005p qPCR System (Agilent Technologies). The final volume for each reaction was 10 μ l with 
300 nM (400 nM for TOP1) of corresponding gene specific primers (Table 1), and 1 μ l of total cDNA. A positive 
control/calibrator cDNA sample synthesized from commercial available Human Universal Reference Total RNA 
(hRNA; Clontech) was included on each plate. A negative water control was included in each run. The thermal 
cycling was initiated at 95 °C for 20 s followed by 40 cycles of 5 s at 95 °C and 30 s at the optimal annealing temper-
ature for each gene (Table 1). If primer dimers were observed, an additional acquisition step for 15 s in each cycle 
was added to avoid primer dimers detection (Table 1 and Fig. S1). Dissociation curve analyses were carried out at 
the end of each run for PCR product verification (Fig. S1).
Data analysis. The stabilities of the RG candidates were accessed using four methods: Genorm16, 
NormFinder18, BestKeeper17 and the comparative Δ Ct method15 combined in the online package RefFinder 
which includes an overall comprehensive analyses of the four methods20 (http://fulxie.0fees.us). The mean 
Ct-values for each sample were normalized using a Human Universal Reference cDNA as a calibrator as described 
by39. Furthermore, the Ct-values were corrected for the efficiencies for each gene. Relative quantities were calcu-
lated using geometric averaging of multiple reference genes55.
Statistics. Data are displayed as mean ± SEM. Gaussian distribution was evaluated using the D’Agostino- 
Pearson omnibus normality test. Homogeneity of variance was evaluated using Levene’s test. Outliers were 
removed using the ROUT procedure with maximum false discovery rate (FDR) Q = 1%. Statistical analyses 
were conducted in GraphPad Prism 6.01 (GraphPad Software) and the Real Statistics Resource Pack software 
v. 4.8 using non-paired parametric Student’s t-test, Welch’s t-test for unequal variances, one-way ANOVA fol-
lowed by Tukey’s multiple comparison range test, Welch’s ANOVA followed by Games-Howell post hoc test, and 
Bonferroni corrected Pearson product-moment correlation or Mann-Whitney U test, and Bonferroni corrected 
Spearman rank correlation. Chi-square test was used to assess the gender frequency. p-values below 0.05 were 
considered statistically significant.
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